Evidence map›Paper›PMID 37533486›Full record

ArticleSAGE open medical case reports2023

Anti-GBM disease with positive serum anti-GBM antibodies but negative IgG deposition: A case report.

Kimia Kazemzadeh, Elham Kabiri Naeini, Firouzeh Moeinzadeh, Azar Naimi

Open access · goldAbstract readCase Reports
In one paragraph

Article in SAGE open medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kimia KazemzadehStudents' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-6948-4838
Elham Kabiri NaeiniIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Firouzeh MoeinzadehIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Azar NaimiDepartment of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IRUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-glomerular basement membrane antibodies are significantly specific for detecting anti-glomerular basement membrane disease. These antibodies are typically targeted against the non-collagenous (NC1) domain of the alpha 3 chain of type IV collagen and, to a lesser extent, the α4(IV) or α5(IV) chains, which create a triple-helical structure in the glomerular basement membrane. The modification of the hexameric structure of NC1 (α3(IV)) results in the exposure of new epitopes, leading to an immune reaction and the subsequent deposition of linear antibodies along the glomerular basement membrane, culminating in crescentic glomerulonephritis. Anti-glomerular basement membrane antibodies that are positive are believed to be pathogenic and capable of binding to the glomerular basement membrane in vivo, particularly in the context of rapidly progressive glomerulonephritis. Herein, we present a patient with positive serum anti-glomerular basement membrane antibodies but negative IgG deposition. The current findings are significant for raising physicians' awareness of the probable errors in detecting anti-glomerular basement membrane antibody disease as a possible cause of irreversible kidney failure.

Indexed as

anti-GBM diseaseAnti-glomerular basement membrane antibodiescrescentic glomerulonephritisglomerulonephritisIgG deposition

Identifiers

PMID37533486
PMCPMC10392201
OpenAlexW4385434175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.